Citations

Clear

1011 citation(s) found for "Barry, WT".

Prevalence and incidence of diastolic dysfunction in atrial fibrillation: clinical implications
Naser, Jwan A. , Scott, Christopher G. , Kennedy, Austin M , Pellikka, Patricia A. , Lin, Grace , Pislaru, Sorin V. , Borlaug, Barry A. , Scott, Christopher , Kennedy, Austin M , Pellikka, Patricia A , Sabbah, Michael S. , Borlaug, Barry A , Naser, Jwan A , Lee, Eunjung

Mayo Clinic

European Heart Journal | August 28, 2023 | Volume: 44 | Issue: 48 | Pages: 5049-5060

10.1093/eurheartj/ehad592 | PMID 37639219 Get It

Abstract Background and Aims Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are intimately associated disorders; HFpEF may be overlooked in AF when symptoms are simply attributed to dysrhythmia, and incident AF may identify patients at risk for developing diastolic dysfunction (DD). This study aimed to investigate the prevalence and incidence of DD in patients with new-onset AF compared with sinus rhythm (SR). Methods Adults with new-onset AF (n = 1747) or SR (n = 29 623) and no structural heart disease were identified. Propensity score matching was performed (1:3 ratio) between AF and SR based on age, sex, body mass index, and comorbidities. Severe DD (SDD) was defined by ≥3/four abnormal parameters (medial e’, medial E/e’, tricuspid regurgitation velocity, and left atrial volume index) and ≥moderate DD (>MDD) by ≥2/4. Annualized changes in DD indices were determined. Results New-onset AF was independently associated with SDD (8% vs. 3%) and ≥MDD (25% vs. 16%); 62% of patients with AF had high-risk H2FPEF scores, and 5% had clinically recognized HFpEF. Over a median follow-up of 3.2 (interquartile range 1.6–5.8) years, DD progressed two–four-fold more rapidly in those with new-onset AF (P < .001 for all). The risk for incident DD was increased in new-onset AF [hazard ratio (95% confidence interval) 2.69 (2.19–3.32) for SDD and 1.73 (1.49–2.02) for ≥MDD]. Conclusions Patients with new-onset AF display high-risk features for HFpEF at diagnosis, emphasizing the importance of evaluating for HFpEF among symptomatic patients with AF. Patients with new-onset AF have accelerated progression in DD over time, which may identify patients with preclinical HFpEF, where preventive therapies may be tested.
Determinants and prognostic implications of left atrial reverse remodelling after coarctation of aorta repair in adults
Egbe, Alexander C. , Younis, Ahmed , Miranda, William R. , Jain, C. Charles , Connolly, Heidi M. , Borlaug, Barry A.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | August 16, 2023 | Volume: 25 | Issue: 2 | Pages: 249-256

10.1093/ehjci/jead203 | PMID 37585542 Get It

Abstract Aims Left atrial (LA) dysfunction and atrial fibrillation are also relatively common in adults with coarctation of aorta (COA), and the severity of LA dysfunction is associated with a higher risk of atrial fibrillation in this population. The purpose of this study was to determine whether LA function improved after COA repair (LA reverse remodelling), and the relationship between LA reverse remodelling and atrial fibrillation. Methods and results Retrospective cohort study of adults undergoing COA repair (2003–20). LA reservoir strain was assessed pre intervention and 12–24 months post intervention, using speckle tracking echocardiography. Incident atrial fibrillation was assessed from COA repair to last follow-up. Of 261 adults who underwent COA repair [age 37 ± 13 years; males 148 (57%)], 124 (47%) and 137 (53%) presented with native vs. recurrent COA, respectively. Of 261 patients, 231 (82%) and 48 (18%) underwent surgical and transcatheter COA repair, respectively. The LA reservoir strain increased from 32 ± 8% (pre intervention) to 39 ± 7% (post intervention), yielding a relative increase of 21 ± 5%. Older age [β ± standard error (SE) −0.16 ± 0.09 per 5 years, P = 0.02], higher systolic blood pressure (β ± SE −0.12 ± 0.04 per 5 mmHg, P = 0.005), and higher residual COA mean gradient (β ± SE −0.17 ± 0.06 per 5 mmHg, P = 0.002) post intervention were associated with less LA reverse remodelling, after adjustment for sex, hypertension diagnosis, and left ventricular indices. LA reverse remodelling (hazard ratio 0.97, 95% confidence interval 0.96–0.98 per 1% increase from pre-intervention LA function, P = 0.006) was associated with a lower risk of atrial fibrillation after adjustment for age, sex, pre-intervention LA reservoir strain, and history of atrial fibrillation. Conclusion COA repair resulted in improved LA function and decreased risk for atrial fibrillation, especially in patients without residual hypertension or significant residual COA gradient.
NEIM-05 PURSUE: RESULTS FROM A PROSPECTIVE, PHASE 2B TRIAL TO DEFINE IMAGE INTERPRETATION CRITERIA FOR18F-FLUCICLOVINE-PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY
Kotecha, Rupesh , Chiang, Veronica , Nabavizadeh, Ali , Zan, Elçin , Peddi, Srinivas, Siegel, Barry A. , Ware, Marcus, Holmes, Robin, Chau, Albert, Chao, Samuel T. , Tom, Martin C. , Sulman, Erik P. , Huang, Jiayi , Brem, Steven , Kesari, Santosh , Parent, Ephraim E. , Pope, Whitney B. , Teoh, Eugene , Aboian, Mariam

Mayo Clinic

Neuro-Oncology Advances | August 4, 2023 | Volume: 5 | Issue: Supplement_3 | Pages: iii15-iii15

10.1093/noajnl/vdad070.057 Get It

Abstract BACKGROUND After radiation therapy (RT) for brain metastases (BM), differentiating radiation necrosis from tumor recurrence remains challenging. PURSUE (NCT04410367) evaluated various measures of lesion 18F-fluciclovine uptake to establish image interpretation criteria (IIC) for 18F-fluciclovine-PET to accurately diagnose recurrent BM. METHODS Patients with solid tumor BM and a previously irradiated ‘reference’ lesion equivocal for recurrence on MRI who were scheduled for craniotomy underwent 18F-fluciclovine-PET (185 MBq) <42 days post-MRI and 1-21 days pre-craniotomy. Lesion 18F-fluciclovine uptake was qualitatively rated as ‘mild’ (up to blood pool), ‘moderate’ (above blood pool to parotid gland), or ‘marked’ (above parotid gland) by three independent blinded readers. The primary endpoint was diagnostic performance of different uptake thresholds on qualitative reads vs central histopathology. Secondary endpoints included diagnostic performance, based on different thresholds, of quantitative (e.g., lesion standardized uptake value [SUV]) and dynamic measures. IIC were determined by committee and subsequently used to assess the diagnostic performance of 18F-fluciclovine. RESULTS All 23 reference lesions from 23 enrolled patients underwent histopathological analysis; 10 (43%) were pathologically-confirmed BM recurrence. The highest performing qualitative measure was ‘marked’, rendering 92-100% sensitivity and 40-80% specificity across readers. SUVmax was a reader-independent, high-performing quantitative metric (AUC 0.87, SUVmax threshold 4.8, 80% sensitivity, 85% specificity). Dynamic measures did not add diagnostic value. Thus, IIC was established as: “Lesions with 18F-fluciclovine uptake of SUVmax equal to or greater than 4.8, or visually greater than the parotid gland, should be considered suspicious for recurrence. Otherwise, recurrence should be considered unlikely.” Application of the IIC resulted in 80% sensitivity, 77-85% specificity, 73-80% PPV, and 83-85% NPV across the readers. CONCLUSIONS PURSUE is the first prospective, multicenter trial to establish IIC for 18F-fluciclovine-PET for suspected recurrent BM after RT, verified by histopathology. Finalized IIC demonstrated excellent diagnostic performance for 18F-fluciclovine and will help evaluate 18F-fluciclovine-PET in future studies.
Transfusion reactions associated with COVID‐19 convalescent plasma in outpatient clinical trials
Huamán, Moisés A. , Patel, Bela , Marshall, Christi E., Yarava, Anusha , Heath, Sonya L. , Fukuta, Yuriko , Blair, Janis E. , Spivak, Emily S , Petrini, Joann, Broderick, Patrick , Rausch, William, Cordisco, Marie Elena , Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie , Cruser, Daniel, Oei, Kevin , Abinante, Matthew, Hammitt, Laura L. , Forthal, Donald N. , Cachay, Edward R. , Ram, Malathi , Das, Piyali, Lane, Karen , McBee, Nichol , Gawad, Amy L., Karlen, Nicky, Laeyendecker, Oliver , Ehrhardt, Stephan , Lau, Bryan , Baksh, Sheriza , Shade, David , Ou, Jiangda , Gniadek, Thomas J. , Ziman, Alyssa , Bloch, Evan M. , Gerber, Jonathan M. , Ziman, Alyssa , Bloch, Evan M , Tobian, Aaron A R , Sullivan, David J , Huaman, Moises A , Laeyendecker, Oliver , Raval, Jay S. , Paxton, James H , Mosnaim, Giselle S , Anjan, Shweta , Meisenberg, Barry R. , Levine, Adam C , Shenoy, Aarthi , Currier, Judith S. , Broderick, Patrick B., Sutcliffe, Catherine G , Zand, Martin S. , Kassaye, Seble , Wang, Ying , Ford, Daniel E , Pekosz, Andrew , Klein, Sabra L , Casadevall, Arturo , Hanley, Daniel F. , Shoham, Shmuel , Gebo, Kelly A , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

Transfusion | August 3, 2023 | Volume: 63 | Issue: 9 | Pages: 1639-1648

10.1111/trf.17485 | PMID 37534607 Get It

AbstractBackgroundCOVID‐19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS‐CoV‐2 infection. We assessed the safety of outpatient CCP transfusions administered during clinical trials.Study Design and MethodsWe analyzed data pertaining to transfusion‐related reactions from two randomized controlled trials in the U.S. that evaluated the efficacy of CCP versus control plasma in various ambulatory settings. Multivariable logistic regression was used to assess whether CCP was associated with transfusion reactions, after adjusting for potential confounders.ResultsThe combined study reported 79/1351 (5.9%) adverse events during the transfusion visit, with the majority 62/1351 (4.6%) characterized by mild, allergic‐type findings of urticaria, and/or pruritus consistent with minor allergic transfusion reactions; the other reported events were attributed to the patients' underlying disease, COVID‐19, or vasovagal in nature. We found no difference in the likelihood of allergic transfusion reactions between those receiving CCP versus control plasma (adjusted odds ratio [AOR], 0.75; 95% CI, 0.43–1.31). Risk of urticaria and/or pruritus increased with a pre‐existing diagnosis of asthma (AOR, 2.33; 95% CI, 1.16–4.67). We did not observe any CCP‐attributed antibody disease enhancement in participants with COVID‐19 or increased risk of infection. There were no life‐threatening severe transfusion reactions and no patients required hospitalization related to transfusion‐associated complications.DiscussionOutpatient plasma administration was safely performed for nearly 1400 participants. CCP is a safe therapeutic option for outpatients at risk of hospitalization from COVID‐19.
Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial
Borlaug, Barry A. , Reddy, Yogesh N.V. , Sorimachi, Hidemi, Omar, Massar , Popović, Dejana , Alogna, Alessio , Jensen, Michael D. , Carter, Rickey E. , Braun, Amanda, Omar, Massar , Carter, Rickey E , Nishimura, Rick , Borlaug, Barry A , Braun, Amanda

Mayo Clinic

Circulation | August 3, 2023 | Volume: 148 | Issue: 10 | Pages: 834-844

10.1161/circulationaha.123.065134 | PMID 37534453 Get It

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but the hemodynamic mechanisms underlying these benefits remain unclear. This study sought to determine whether treatment with dapagliflozin affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in patients with HFpEF. METHODS: This was a single-center, double-blinded, randomized, placebo-controlled trial testing the effects of 10 mg of dapagliflozin once daily in patients with HFpEF. Patients with New York Heart Association class II or III heart failure, ejection fraction ≥50%, and elevated PCWP during exercise were recruited. Cardiac hemodynamics were measured at rest and during exercise using high-fidelity micromanometers at baseline and after 24 weeks of treatment. The primary end point was a change from baseline in rest and peak exercise PCWPs that incorporated both measurements, and was compared using a mixed-model likelihood ratio test. Key secondary end points included body weight and directly measured blood and plasma volumes. Expired gas analysis was performed evaluate oxygen transport in tandem with arterial lactate sampling. RESULTS: Among 38 patients completing baseline assessments (median age 68 years; 66% women; 71% obese), 37 completed the trial. Treatment with dapagliflozin resulted in reduction in the primary end point of change in PCWP at rest and during exercise at 24 weeks relative to treatment with placebo (likelihood ratio test for overall changes in PCWP; P <0.001), with lower PCWP at rest (estimated treatment difference [ETD], −3.5 mm Hg [95% CI, −6.6 to −0.4]; P =0.029) and maximal exercise (ETD, −5.7 mm Hg [95% CI, −10.8 to −0.7]; P =0.027). Body weight was reduced with dapagliflozin (ETD, −3.5 kg [95% CI, −5.9 to −1.1]; P =0.006), as was plasma volume (ETD, −285 mL [95% CI, −510 to −60]; P =0.014), but there was no significant effect on red blood cell volume. There were no differences in oxygen consumption at 20-W or peak exercise, but dapagliflozin decreased arterial lactate at 20 W (−0.70 ± 0.77 versus 0.37 ± 1.29 mM; P =0.006). CONCLUSIONS: In patients with HFpEF, treatment with dapagliflozin reduces resting and exercise PCWP, along with the favorable effects on plasma volume and body weight. These findings provide new insight into the hemodynamic mechanisms of benefit with sodium-glucose cotransporter-2 inhibitors in HFpEF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04730947.
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
Weiss, Aaron R. , Scharschmidt, Thomas J. , Xue, Wei , Gao, Zhengya, Black, Jennifer O. , Choy, Edwin , Fanburg–Smith, Julie C. , Kao, Simon C. , Kayton, Mark L. , Kessel, Sandy, Lim, Ruth , Million, Lynn , Okuno, Scott H. , Ostrenga, Andrew , Parisi, Marguerite T. , Pryma, Daniel A. , Rosen, Mark, Terezakis, Stephanie , Venkatramani, Rajkumar , Zambrano, Eduardo , Wang, Dian , Hawkins, Douglas S. , Black, Jennifer O , Choy, Edwin , Kao, Simon C , Kayton, Mark L , Lim, Ruth , Million, Lynn , Okuno, Scott , Ostrenga, Andrew , Pryma, Daniel A , Randall, Robert Lor , Shulkin, Barry L , Terezakis, Stephanie A , Venkatramani, Rajkumar , Wang, Dian , Hawkins, Douglas S , Spunt, Sheri L , Weiss, Aaron R , Chen, Yen‐Lin , Davis, Jessica L. , Randall, R. Lor , Shulkin, Barry L. , Spunt, Sheri L.

Mayo Clinic

Journal of Clinical Oncology | July 31, 2023 | Volume: 41 | Issue: 31 | Pages: 4842-4848

10.1200/jco.23.00045 | PMID 37523624 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. ARST1321 was a phase II study designed to compare the near complete pathologic response rate after preoperative chemoradiation with/without pazopanib in children and adults with intermediate-/high-risk chemotherapy-sensitive body wall/extremity non-Rhabdomyosarcoma Soft Tissue Sarcoma (ClinicalTrials.gov identifier: NCT02180867 ). Enrollment was stopped early following a predetermined interim analysis that found the rate of near complete pathologic response to be significantly greater with the addition of pazopanib. As a planned secondary aim of the study, the outcome data for this cohort were analyzed. Eight-five eligible patients were randomly assigned to receive (regimen A) or not receive (regimen B) pazopanib in combination with ifosfamide and doxorubicin + preoperative radiotherapy followed by primary resection at week 13 and then further chemotherapy at week 25. As of December 31, 2021, at a median survivor follow-up of 3.3 years (range, 0.1-5.8 years), the 3-year event-free survival for all patients in the intent-to-treat analysis was 52.5% (95% CI, 34.8 to 70.2) for regimen A and 50.6% (95% CI, 32 to 69.2) for regimen B ( P = .8677, log-rank test); the 3-year overall survival was 75.7% (95% CI, 59.7 to 91.7) for regimen A and 65.4% (95% CI, 48.1 to 82.7) for regimen B ( P = .1919, log-rank test). Although the rate of near complete pathologic response was significantly greater with the addition of pazopanib, outcomes were not statistically significantly different between the two regimens.
Cancer cachexia: learn from yesterday, live for today and hope for tomorrow
Laird, Barry , Jatoi, Aminah

Mayo Clinic

Current Opinion in Supportive & Palliative Care | July 27, 2023 | Volume: 17 | Issue: 3 | Pages: 161-161

10.1097/spc.0000000000000652 | PMID 37499059 Get It

Inspiratory Muscle Strength is Related to Exertional Dyspnoea in Heart Failure with Preserved Ejection Fraction
Warner, Brit, Bruhn, Eric J., Olson, Thomas P. , Bissen, Thomas G. , Smith, Joshua R. , Smith, Joshua R. , Smith, Joshua R , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | July 21, 2023 | Volume: 25 | Issue: 9 | Pages: 1716-1717

10.1002/ejhf.2980 | PMID 37476916 Get It

Clinical Characteristics and Outcomes of Clostridioides difficile Infection in Patients With Left Ventricular Assist Device
Chesdachai, Supavit , Schettle, Sarah , Boilson, Barry A. , Shah, Aditya , Mendoza, Maria A. , Schettle, Sarah D., Shah, Aditya S , Chesdachai, Supavit , Yetmar, Zachary A. , Ranganath, Nischal , Razonable, Raymund R.

Mayo Clinic

ASAIO Journal | June 27, 2023 | Volume: 69 | Issue: 10 | Pages: 950-955

10.1097/mat.0000000000002008 | PMID 37367716 Get It

The literature regarding Clostridioides difficile infection (CDI) in left ventricular assist devices (LVADs) patients is limited. Therefore, we aimed to characterize the clinical course, risk factors, management, and outcomes of LVAD patients who developed CDI. Adult patients who underwent LVAD placement during 2010–2022 and developed CDI were included. To determine risk factors and outcomes, we matched CDI patients with LVAD patients who did not develop CDI. Each CDI case was matched with up to two control subjects by age, sex, and time from LVAD implantation. Forty-seven of 393 LVAD patients (12.0%) developed CDI. The median time from LVAD implantation to CDI was 147 days (interquartile range 22.5–647.0). The most common CDI treatment was oral vancomycin (n = 26, 55.3%). Thirteen patients (27.7%) required treatment extension because of a lack of clinical response. Three patients (6.4%) developed recurrent CDI. When 42 cases were matched to 79 control subjects, antibiotic exposure within 90 days was significantly associated with CDI (adjusted odds ratio 5.77; 95% confidence interval, 1.87–17.74; p = 0.002). Moreover, CDI was associated with 1 year mortality (adjusted hazard ratio 2.62; 95% confidence interval, 1.18–5.82; p = 0.018). This infection occurs most often within the first year after LVAD implantation and was associated with 1 year mortality. Antibiotic exposure is an important risk for CDI.